Coenzyme Q 10 for Patients With Cardiovascular Disease: JACC Focus Seminar.
Level 5 - mechanism / opinion, no new human data
Narrative expert review summarizing literature without systematic methodology
PubMed 33538259 · doi:10.1016/j.jacc.2020.12.009
What was done
This narrative review synthesized mechanistic rationale and existing clinical evidence on Coenzyme Q10 (CoQ10) supplementation in cardiovascular disease, particularly focusing on statin-associated muscle symptoms (SAMS) and heart failure (HF).
What was found
The abstract reports no numerical findings or effect sizes. It notes that while individual trials of CoQ10 for SAMS report conflicting results, meta-analyses support its use. For heart failure, large-scale randomized trials are lacking, though the Q-SYMBIO trial suggested potential benefit as an adjunctive therapy.
Why it matters
It summarizes the clinical context and proposed mechanisms for using CoQ10 to manage statin-induced muscle symptoms and adjunctively in heart failure.
Limits
As a narrative review, it lacks a systematic search protocol and risk-of-bias grading. The underlying literature is constrained by conflicting findings across SAMS trials and a lack of large-scale randomized controlled trials in heart failure populations.